N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Sponsor: Regeneron Pharmaceuticals • ClinicalTrials.gov ID: NCT06787612

Registry updated: 2026-09-14
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab, REGN10597 and a standard chemotherapy drug, pegylated liposomal doxorubicin \[PLD\]), referred to as "combination drugs'. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug and its experimental combinations * How much study drug and fianlimab is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) and its combinations

Interventions

  • Ubamatamab (Drug)
    Administered per the protocol
  • Bevacizumab (Drug)
    Administered per the protocol
  • Cemiplimab (Drug)
    Administered per the protocol
  • Fianlimab (Drug)
    Administered per the protocol
  • PLD (Drug)
    Administered per the protocol
  • Sarilumab (Drug)
    Administered per the protocol
  • REGN10597 (Drug)
    Administered per the protocol

Eligibility criteria

Key Inclusion Criteria: 1. Participants with histologically or cytologically confirmed diagnosis of advanced serous or endometrioid ovarian (regardless of the grade), primary peritoneal, or fallopian tube cancer (clear cell, mucinous, and carcinosarcoma are excluded) 2. Must have progression on prior therapy documented radiographically and must have at least 1 measurable lesion (not previously irradiated) that can be accurately measured by RECIST 1.1 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 4. Adequate organ and bone marrow function, as described in the protocol 5. Platinum-Resistant Ovarian Cancer, as described in the protocol Key Exclusion Criteria: 1. Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study intervention(s) 2. Documented allergic or acute hypersensitivity reaction attributed to antibody treatments or doxorubicin hydrochloride or components of study intervention(s) 3. Another malignancy that is progressing or requires active treatment, as described in the protocol 4. Untreated or active Central Nervous System (CNS) metastases, or carcinomatous meningitis, as described in the protocol 5. Uncontrolled infections including but not limited to human immunodeficiency virus, hepatitis B or hepatitis C infection, or diagnosis of immunodeficiency 6. Moderate to large or ascites, as described in the protocol 7. Bowel obstruction within last 3 months or current need for parenteral nutrition NOTE: Other protocol-defined inclusion/exclusion criteria apply

Conditions

Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer

Locations

  • The University of Alabama at Birmingham — Birmingham, Alabama, United States
  • UC San Diego Health — La Jolla, California, United States
  • Cedars Sinai Medical Center — Los Angeles, California, United States
  • Mayo Clinic Jacksonville — Jacksonville, Florida, United States
  • University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida, United States
  • Advent Health Cancer Institute — Orlando, Florida, United States
  • Tampa General Hospital Cancer Institute — Tampa, Florida, United States
  • University of Chicago — Chicago, Illinois, United States
  • The University of Kansas Cancer Center — Westwood, Kansas, United States
  • Norton Cancer Institute, St. Matthews Clinic — Louisville, Kentucky, United States
  • Massachusetts General Hospital — Boston, Massachusetts, United States
  • Karmanos Cancer Institute — Detroit, Michigan, United States
  • The Ohio State University Comprehensive Cancer Center — Hilliard, Ohio, United States
  • Providence Cancer Institute — Portland, Oregon, United States
  • University of Pittsburgh Medical Center, Magee-Womens Hospital — Pittsburgh, Pennsylvania, United States
  • West Penn Hospital of Allegheny Health Network — Pittsburgh, Pennsylvania, United States
  • Avera Cancer Institute Sioux Falls — Sioux Falls, South Dakota, United States
  • UT Southwestern Medical Center — Dallas, Texas, United States
  • Swedish Cancer Institute — Seattle, Washington, United States
  • University of Wisconsin — Madison, Wisconsin, United States
  • Medical College of Wisconsin — Milwaukee, Wisconsin, United States
  • CancerCare Manitoba — Winnipeg, Manitoba, Canada
  • Princess Margaret Cancer Centre — Toronto, Ontario, Canada
  • Centre de Santé et de Services Sociaux de la Montérégie-Centre — Greenfield Park, Quebec, Canada
  • Jewish General Hospital — Montreal, Quebec, Canada
  • Research Institute - McGill University Health Centre — Montreal, Quebec, Canada
  • Centre Hospitalier Universitaire (CHU) de Quebec - Universite Laval — Québec, Canada
  • National Cancer Center — Gyeonggi-do, Gyeonggi-do, South Korea
  • Seoul National University Bundang Hospital — Seongnam-si, Gyeonggi-do, South Korea
  • Gachon University Gil Medical Center — Incheon, Seoul, South Korea
  • Keimyung University Dongsan Hospital — Daegu, South Korea
  • Severance Hospital Yonsei University Health System — Seoul, South Korea
  • Asan Medical Center, Univ. of Ulsan — Seoul, South Korea
  • Samsung Medical Center — Seoul, South Korea
  • Gangnam Severance Hospital — Seoul, South Korea
  • Seoul National University Hospital — Seoul, South Korea
  • Korea University Guro Hospital — Seoul, South Korea
  • Changhua Christian Hospital — Changhua, Changhua City, Taiwan
  • Chi Mei Medical Center — Tainan, Taiwan
  • Mackay Memorial Hospital — Taipei, Taiwan
  • National Taiwan University Hospital — Taipei, Taiwan
  • Taipei Veterans General Hospital — Taipei, Taiwan
  • Tri-Service General Hospital — Taipei, Taiwan
  • Taipei Municipal Wan Fang Hospital — Taipei, Taiwan
  • Medicalpark Seyhan Hospital — Seyhan, Adana, Turkey (Türkiye)
  • Hacettepe University — Altındağ, Ankara, Turkey (Türkiye)
  • Medipol University Hospital — Istanbul, Bagcilar, Turkey (Türkiye)
  • Ege Universitesi Tip Fakultesi Hastanesi — Bornova, İzmir, Turkey (Türkiye)
  • Gaziantep Medicalpoint Hospital — Gaziantep, Sehitkamil, Turkey (Türkiye)
  • Baskent University — Adana, Turkey (Türkiye)
  • Sbu Doctor Abdurrahman Yurtaslan Ankara Onkoloji Suam — Ankara, Turkey (Türkiye)
  • Ankara Bilkent City Hospital — Ankara, Turkey (Türkiye)
  • Memorial Ankara Hospital — Ankara, Turkey (Türkiye)
  • Cerrahpasa Medical Faculty At Istanbul University Cerrahpasa — Istanbul, Turkey (Türkiye)
  • Izmir Ekonomi Universitesi (IEU) Medical Point Izmir Hastanesi (Izmir Economy University Medical Point Izmir Hospital) — Izmir, Turkey (Türkiye)
  • Sakarya University - Education and Research Hospital — Sakarya, Turkey (Türkiye)
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record